Thanos Stavropoulos

Dr. Thanos Stavropoulos

Pfizer Center for Digital Innovation (CDI), Thessaloníki, Kentrikí Makedonía, Greece
orcid

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 May 2020 in Sensors
Verified
Journal Article
Open access
PDF file
Thanos StavropoulosThanos Stavropoulos
Thanos Stavropoulos
APAsterios Papastergiou
Asterios Papastergiou
Lampros MpaltadorosLampros Mpaltadoros
Lampros Mpaltadoros
Spiros NikolopoulosSpiros Nikolopoulos
Spiros Nikolopoulos
Ioannis KompatsiarisIoannis Kompatsiaris
Ioannis Kompatsiaris
The increasing ageing global population is causing an upsurge in ailments related to old age, primarily dementia and Alzheimer’s disease, frailty, Parkinson’s, and cardiovascular disease, but also a general need for general eldercare as well as active and healthy ageing. In turn, there is a need for constant monitoring and assistance, intervention, and support, causing a considerable financial and human burden on individuals and their caregivers. Interconnected sensing technology, such as IoT wearables and devices, present a promising solution for objective, reliable, and remote monitoring, assessment, and support through ambient assisted living. This paper presents a review of such solutions including both earlier review studies and individual case studies, rapidly evolving in the last decade. In doing so, it examines and categorizes them according to common aspects of interest such as health focus, from specific ailments to general eldercare; IoT technologies, from wearables to smart home sensors; aims, from assessment to fall detection and indoor positioning to intervention; and experimental evaluation participants duration and outcome measures, from acceptability to accuracy. Statistics drawn from this categorization aim to outline the current state-of-the-art, as well as trends and effective practices for the future of effective, accessible, and acceptable eldercare with technology.

14 September 2016 in Journal of Alzheimer’s Disease
Verified
Journal Article
Closed access
PDF file
Ioulietta LazarouIoulietta Lazarou
Ioulietta Lazarou
AKAnastasios Karakostas
Anastasios Karakostas
Thanos StavropoulosThanos Stavropoulos
Thanos Stavropoulos
TTTheodoros Tsompanidis
Theodoros Tsompanidis
GMGeorgios Meditskos
Georgios Meditskos
Magda TsolakiMagda Tsolaki
Magda Tsolaki
Background: Assistive technology, in the form of a smart home environment, is employed to support people with dementia. Objectives: To propose a system for continuous and objective remote monitoring of problematic daily living activity areas and design personalized interventions based on system feedback and clinical observations for improving cognitive function and health-related quality of life. Methods: The assistive technology of the proposed system, including wearable, sleep, object motion, presence, and utility usage sensors, was methodically deployed at four different home installations of people with cognitive impairment. Detection of sleep patterns, physical activity, and activities of daily living, based on the collected sensor data and analytics, was available at all times through comprehensive data visualization solutions. Combined with clinical observation, targeted psychosocial interventions were introduced to enhance the participants’ quality of life and improve their cognitive functions and daily functionality. Meanwhile, participants and their caregivers were able to visualize a reduced set of information tailored to their needs. Results: Overall, paired-sample t -test analysis of monitored qualities revealed improvement for all participants in neuropsychological assessment. Moreover, improvement was detected from the beginning to the end of the trial, in physical condition and in the domains of sleep. Detecting abnormalities via the system, for example in sleep quality, such as REM sleep, has proved to be critical to assess current status, drive interventions, and evaluate improvements in a reliable manner. Conclusion: It has been proved that the proposed system is suitable to support clinicians to reliably drive and evaluate clinical interventions toward quality of life improvement of people with cognitive impairment.

10 February 2024 in Sensors
Verified
Journal Article
Open access
PDF file
PKPanagiotis Kapetanidis
Panagiotis Kapetanidis
FKFotios Kalioras
Fotios Kalioras
CTConstantinos Tsakonas
Constantinos Tsakonas
PTPantelis Tzamalis
Pantelis Tzamalis
GKGeorge Kontogiannis
George Kontogiannis
SNSotiris Nikoletseas
Sotiris Nikoletseas
Respiratory diseases represent a significant global burden, necessitating efficient diagnostic methods for timely intervention. Digital biomarkers based on audio, acoustics, and sound from the upper and lower respiratory system, as well as the voice, have emerged as valuable indicators of respiratory functionality. Recent advancements in machine learning (ML) algorithms offer promising avenues for the identification and diagnosis of respiratory diseases through the analysis and processing of such audio-based biomarkers. An ever-increasing number of studies employ ML techniques to extract meaningful information from audio biomarkers. Beyond disease identification, these studies explore diverse aspects such as the recognition of cough sounds amidst environmental noise, the analysis of respiratory sounds to detect respiratory symptoms like wheezes and crackles, as well as the analysis of the voice/speech for the evaluation of human voice abnormalities. To provide a more in-depth analysis, this review examines 75 relevant audio analysis studies across three distinct areas of concern based on respiratory diseases’ symptoms: (a) cough detection, (b) lower respiratory symptoms identification, and (c) diagnostics from the voice and speech. Furthermore, publicly available datasets commonly utilized in this domain are presented. It is observed that research trends are influenced by the pandemic, with a surge in studies on COVID-19 diagnosis, mobile data acquisition, and remote diagnosis systems.

24 November 2016 in Sensors
Verified
Journal Article
Open access
PDF file
BKBasel Kikhia
Basel Kikhia
Thanos StavropoulosThanos Stavropoulos
Thanos Stavropoulos
SAStelios Andreadis
Stelios Andreadis
NKNiklas Karvonen
Niklas Karvonen
Ioannis KompatsiarisIoannis Kompatsiaris
Ioannis Kompatsiaris
CMCatharina Melander
Catharina Melander
Stress is a common problem that affects most people with dementia and their caregivers. Stress symptoms for people with dementia are often measured by answering a checklist of questions by the clinical staff who work closely with the person with the dementia. This process requires a lot of effort with continuous observation of the person with dementia over the long term. This article investigates the effectiveness of using a straightforward method, based on a single wristband sensor to classify events of “Stressed” and “Not stressed” for people with dementia. The presented system calculates the stress level as an integer value from zero to five, providing clinical information of behavioral patterns to the clinical staff. Thirty staff members participated in this experiment, together with six residents suffering from dementia, from two nursing homes. The residents were equipped with the wristband sensor during the day, and the staff were writing observation notes during the experiment to serve as ground truth. Experimental evaluation showed relationships between staff observations and sensor analysis, while stress level thresholds adjusted to each individual can serve different scenarios.

23 April 2021 in Alzheimer's Research & Therapy
Verified
Journal Article
Open access
PDF file
TCthe RADAR-AD Consortium
the RADAR-AD Consortium
MMMarijn Muurling
Marijn Muurling
CBCasper de Boer
Casper de Boer
RKRouba Kozak
Rouba Kozak
DRDorota Religa
Dorota Religa
PVPieter Jelle Visser
Pieter Jelle Visser
Background: Functional decline in Alzheimer’s disease (AD) is typically measured using single-time point subjective rating scales, which rely on direct observation or (caregiver) recall. Remote monitoring technologies (RMTs), such as smartphone applications, wearables, and home-based sensors, can change these periodic subjective assessments to more frequent, or even continuous, objective monitoring. The aim of the RADAR-AD study is to assess the accuracy and validity of RMTs in measuring functional decline in a real-world environment across preclinical-to-moderate stages of AD compared to standard clinical rating scales. Methods: This study includes three tiers. For the main study, we will include participants (n = 220) with preclinical AD, prodromal AD, mild-to-moderate AD, and healthy controls, classified by MMSE and CDR score, from clinical sites equally distributed over 13 European countries. Participants will undergo extensive neuropsychological testing and physical examination. The RMT assessments, performed over an 8-week period, include walk tests, financial management tasks, an augmented reality game, two activity trackers, and two smartphone applications installed on the participants’ phone. In the first sub-study, fixed sensors will be installed in the homes of a representative sub-sample of 40 participants. In the second sub-study, 10 participants will stay in a smart home for 1 week. The primary outcome of this study is the difference in functional domain profiles assessed using RMTs between the four study groups. The four participant groups will be compared for each RMT outcome measure separately. Each RMT outcome will be compared to a standard clinical test which measures the same functional or cognitive domain. Finally, multivariate prediction models will be developed. Data collection and privacy are important aspects of the project, which will be managed using the RADAR-base data platform running on specifically designed biomedical research computing infrastructure. Results: First results are expected to be disseminated in 2022. Conclusion: Our study is well placed to evaluate the clinical utility of RMT assessments. Leveraging modern-day technology may deliver new and improved methods for accurately monitoring functional decline in all stages of AD. It is greatly anticipated that these methods could lead to objective and real-life functional endpoints with increased sensitivity to pharmacological agent signal detection.

12 April 2021 in Frontiers in Aging Neuroscience
Verified
Journal Article
Open access
Thanos StavropoulosThanos Stavropoulos
Thanos Stavropoulos
ILIoulietta Lazarou
Ioulietta Lazarou
ADAna Diaz
Ana Diaz
DGDianne Gove
Dianne Gove
JGJean Georges
Jean Georges
IKIoannis Kompatsiaris
Ioannis Kompatsiaris
Background: Alzheimer's Disease (AD) impairs the ability to carry out daily activities, reduces independence and quality of life and increases caregiver burden. Our understanding of functional decline has traditionally relied on reports by family and caregivers, which are subjective and vulnerable to recall bias. The Internet of Things (IoT) and wearable sensor technologies promise to provide objective, affordable, and reliable means for monitoring and understanding function. However, human factors for its acceptance are relatively unexplored.Objective: The Public Involvement (PI) activity presented in this paper aims to capture the preferences, priorities and concerns of people with AD and their caregivers for using monitoring wearables. Their feedback will drive device selection for clinical research, starting with the study of the RADAR-AD project.Method: The PI activity involved the Patient Advisory Board (PAB) of the RADAR-AD project, comprised of people with dementia across Europe and their caregivers (11 and 10, respectively). A set of four devices that optimally represent various combinations of aspects and features from the variety of currently available wearables (e.g., weight, size, comfort, battery life, screen types, water-resistance, and metrics) was presented and experienced hands-on. Afterwards, sets of cards were used to rate and rank devices and features and freely discuss preferences.Results: Overall, the PAB was willing to accept and incorporate devices into their daily lives. For the presented devices, the aspects most important to them included comfort, convenience and affordability. For devices in general, the features they prioritized were appearance/style, battery life and water resistance, followed by price, having an emergency button and a screen with metrics. The metrics valuable to them included activity levels and heart rate, followed by respiration rate, sleep quality and distance. Some concerns were the potential complexity, forgetting to charge the device, the potential stigma and data privacy.Conclusions: The PI activity explored the preferences, priorities and concerns of the PAB, a group of people with dementia and caregivers across Europe, regarding devices for monitoring function and decline, after a hands-on experience and explanation. They highlighted some expected aspects, metrics and features (e.g., comfort and convenience), but also some less expected (e.g., screen with metrics).